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:   breast cancer
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:   Epithelial splicing regulatory protein 1

GEO

:   Gene Expression Omnibus

*GINS1*

:   GINS complex subunit 1

*HMGB3*

:   High Mobility Group Box 3

*MAGOHB*

:   Mago Homolog B

miRNA

:   microRNA

RISC

:   RNA‐induced silencing complex

*SRPK1*

:   Serine/Arginine‐Rich Splicing Factor Kinase 1

TCGA

:   The Cancer Genome Atlas

*TPD52*

:   Tumor Protein D52

*VANGL1*

:   Vang‐like protein 1

1. Introduction {#mol212602-sec-0001}
===============

Breast cancer (BrCa) is the most common malignancy among women, and \~ 2 million cases are newly diagnosed each year, resulting in more than 620 000 deaths annually (Bray *et al.*, [2018](#mol212602-bib-0006){ref-type="ref"}; Ferlay *et al.*, [2015](#mol212602-bib-0010){ref-type="ref"}). In the general population, \~ 12% of women will develop BrCa in their lifetime (Howlader et al., 2017). In contrast, \~ 70% of women who inherit *BRCA1* or *BRCA2* mutations will develop BrCa by 80 years of age (Kuchenbaecker *et al.*, [2017](#mol212602-bib-0024){ref-type="ref"}). A recent study reported that germline mutations in *TP53* and *PTEN* also increase the risk of BrCa development (Economopoulou *et al.*, [2015](#mol212602-bib-0009){ref-type="ref"}).

Based on gene expression signature analysis, BrCa can be classified into intrinsic molecular subtypes (Perou *et al.*, [2000](#mol212602-bib-0041){ref-type="ref"}; Sotiriou *et al.*, [2003](#mol212602-bib-0046){ref-type="ref"}). According to the 12th St Gallen International Breast Cancer Conference, BrCa can be classified into the following five subtypes, which can facilitate the selection of treatment strategies: luminal‐A, luminal‐B \[human epidermal growth factor receptor 2 (HER2)‐positive\], luminal‐B (HER2‐negative), HER2‐positive, and triple negative (Goldhirsch *et al.*, [2011](#mol212602-bib-0013){ref-type="ref"}). These intrinsic molecular subtypes are related to the biological features of BrCa and are essential for treatment selection.

Many studies have indicated that noncoding RNAs derived from the human genome are functional and play pivotal roles in various cellular activities, e.g. cell proliferation, movement, and death (Gebert and MacRae, [2019](#mol212602-bib-0012){ref-type="ref"}; Treiber *et al.*, [2019](#mol212602-bib-0051){ref-type="ref"}). Among noncoding RNAs, microRNA (miRNA) are short RNA molecules (19--22‐nucleotide single‐stranded RNA molecules) that play roles in regulating protein‐coding and noncoding RNA expression in cells (Gebert and MacRae, [2019](#mol212602-bib-0012){ref-type="ref"}; Treiber *et al.*, [2019](#mol212602-bib-0051){ref-type="ref"}). Importantly, a single miRNA regulates many RNA transcripts, and bioinformatics studies have shown that more than half of the RNA molecules transcribed from the genome are controlled by miRNA (Bartel, [2009](#mol212602-bib-0004){ref-type="ref"}). In cancer cells, intracellular RNA networks are disrupted due to the influence of abnormally expressed miRNA. These aberrantly expressed miRNA play critical roles in the malignant transformation of cancer cells.

To identify tumor‐suppressive or oncogenic miRNA in cancers, miRNA expression signatures provide valuable information. RNA‐sequencing technology is suitable for producing miRNA signatures. Recently, we reported the miRNA expression signature of triple‐negative BrCa (TNBC), and 104 miRNA (56 upregulated miRNA and 48 downregulated miRNA) were found to be significantly dysregulated in TNBC tissues (Toda *et al.*, [2018](#mol212602-bib-0050){ref-type="ref"}). TNBC is a subtype of BrCa in which estrogen receptor (ER), progesterone receptor, and HER2 are not expressed; \~ 15--20% of BrCa cases are TNBC (Foulkes *et al.*, [2010](#mol212602-bib-0011){ref-type="ref"}; Goldhirsch *et al.*, [2011](#mol212602-bib-0013){ref-type="ref"}). TNBC is highly aggressive in nature, and metastases are frequently observed. Therefore, the prognosis of TNBC is worse than that of other subtypes of BrCa (Foulkes *et al.*, [2010](#mol212602-bib-0011){ref-type="ref"}; Goldhirsch *et al.*, [2011](#mol212602-bib-0013){ref-type="ref"}). Based on our TNBC signatures, we identified tumor‐suppressive *miR‐204‐5p* and novel oncogenic genes regulated by this miRNA (Toda *et al.*, [2018](#mol212602-bib-0050){ref-type="ref"}). Interestingly, several *miR‐204‐5p* target genes were found to be closely associated with BrCa pathogenesis (Toda *et al.*, [2018](#mol212602-bib-0050){ref-type="ref"}). The discovery of oncogenic networks mediated by tumor‐suppressive miRNA will contribute to the elucidation of the molecular mechanisms mediating the pathogenesis of BrCa.

Breast cancer is a heterogeneous cancer, and treatment strategies differ for each subgroup (Foulkes *et al.*, [2010](#mol212602-bib-0011){ref-type="ref"}; Goldhirsch *et al.*, [2011](#mol212602-bib-0013){ref-type="ref"}; Perou *et al.*, [2000](#mol212602-bib-0041){ref-type="ref"}; Sotiriou *et al.*, [2003](#mol212602-bib-0046){ref-type="ref"}). Thus, elucidation of the universal molecular pathways mediating BrCa will lead to the development of new treatment strategies for this disease. Accordingly, in this study, we created the RNA‐sequencing‐based miRNA expression signature of BrCa using clinical BrCa specimens, including ER‐positive, HER2‐positive, and TNBC specimens. In total, 64 miRNA were identified as candidate tumor‐suppressive miRNA in BrCa cells. Analysis of our BrCa signature revealed that several miRNA duplexes (guide strand/passenger strand) derived from pre‐miRNA were downregulated in BrCa tissues. Despite the general consensus that passenger strands derived from miRNA duplexes have no regulatory activity, our recent studies have revealed that some passenger strands actually function by targeting several genes (Mah *et al.*, [2010](#mol212602-bib-0032){ref-type="ref"}; McCall *et al.*, [2017](#mol212602-bib-0034){ref-type="ref"}).

Based on our current miRNA signature of BrCa, the expression levels of both strands of the *miR‐101* duplex (*miR‐101‐5p*: the passenger strand and *miR‐101‐3p*: the guide strand) were significantly reduced in cancer tissues, suggesting that these miRNA have tumor‐suppressive functions. Many previous reports have demonstrated that *miR‐101‐3p* acts as a tumor‐suppressive miRNA in various cancers (Wang *et al.*, [2018](#mol212602-bib-0054){ref-type="ref"}). In contrast to *miR‐101‐3p*, the functional significance of *miR‐101‐5p* and RNA networks regulated by this miRNA in cancer cells is poorly understood. Accordingly, in this study, we showed that ectopic expression of *miR‐101‐5p* attenuated aggressive phenotypes, e.g. proliferation, migration, and invasion, in BrCa cells. Moreover, GINS complex subunit 1 (*GINS1*) was directly controlled by *miR‐101‐5p* in BrCa cells, and its expression contributed to BrCa oncogenesis.

2. Materials and methods {#mol212602-sec-0002}
========================

2.1. Collection of clinical breast cancer specimens, breast epithelial specimens, and BrCa cell lines {#mol212602-sec-0003}
-----------------------------------------------------------------------------------------------------

To construct the miRNA expression signature of BrCa, 20 clinical tissue specimens (five specimens each for ER‐positive BrCa, HER2‐positive BrCa, TNBC, and normal breast epithelium) were collected following surgical resection at Gunma University Hospital.

To validate the expression levels of miRNA and target genes, 27 clinical specimens (18 BrCa specimens and nine normal breast epithelial tissues) were collected at Kagoshima University Hospital. Twenty‐one paraffin blocks of BrCa specimens were used for immunostaining. The clinical features of these patients are shown in Table [1](#mol212602-tbl-0001){ref-type="table"}. Informed consent was obtained from all patients. This study was approved by the Bioethics Committee of Gunma University (approval nos 2016‐023 and 2017‐167) and Kagoshima University (approval no. 160038:28‐65). The study methodologies conformed to the standards set by the Declaration of Helsinki.

###### 

Clinical features of 50 patients with BrCa.

           Age   T factors   Lymph node metastasis   Stage   ER         PgR        HER2       Ki67          Lymphatic invasion   Venous invasion   Nuclear Grade   Remarks
  -------- ----- ----------- ----------------------- ------- ---------- ---------- ---------- ------------- -------------------- ----------------- --------------- ------------
  BC1      66    1           Yes                     ⅡA      Positive   Positive   Negative   5--10         1                    0                 3               RNA seq.
  BC2      66    1           No                      Ⅰ       Positive   Positive   Negative   18--23        0                    0                 2               RNA seq.
  BC3      50    2           Yes                     ⅡB      Positive   Positive   Negative   10--15        1                    0                 3               RNA seq.
  BC4      47    2           Yes                     ⅡB      Positive   Positive   Negative   15--20        1                    0                 2               RNA seq.
  BC5      70    2           Yes                     ⅡB      Positive   Positive   Negative   15--20        1                    0                 2               RNA seq.
  BC6      69    2           No                      ⅡA      Negative   Negative   Positive   58            1                    0                 3               RNA seq.
  BC7      59    2           No                      ⅡA      Positive   Positive   Positive   50--60        0                    0                 3               RNA seq.
  BC8      48    2           No                      ⅡA      Positive   Negative   Positive   22--27        1                    1                 3               RNA seq.
  BC9      68    2           Yes                     ⅡB      Positive   Negative   Positive   83            1                    1                 3               RNA seq.
  BC10     67    2           No                      ⅡA      Negative   Negative   Positive   20--30        0                    0                 3               RNA seq.
  BC11     58    2           No                      ⅡA      Negative   Negative   Negative   70--80        0                    0                 3               RNA seq.
  BC12     44    2           No                      ⅡA      Negative   Negative   Negative   70--80        0                    0                 3               RNA seq.
  BC13     83    2           No                      ⅡA      Negative   Negative   Negative   60            0                    0                 3               RNA seq.
  BC14     66    2           No                      ⅡA      Negative   Negative   Negative   Unavailable   0                    1                 3               RNA seq.
  BC15     47    2           No                      ⅡA      Negative   Negative   Negative   70--80        0                    0                 3               RNA seq.
  BC16     79    2           No                      IIA     Positive   Positive   Negative   11            0                    0                 1               RT‐PCR/IHC
  BC17     49    2           Yes                     ⅢA      Positive   Positive   Negative   4             1                    0                 1               RT‐PCR/IHC
  BC18     82    1a          No                      Ⅰ       Positive   Positive   Negative   10            0                    0                 1               RT‐PCR/IHC
  BC19     56    2           No                      IIA     Positive   Positive   Negative   13            0                    0                 3               RT‐PCR/IHC
  BC20     44    1c          No                      Ⅰ       Positive   Positive   Negative   26            1                    0                 1               RT‐PCR/IHC
  BC21     86    1c          Yes                     IIA     Positive   Positive   Negative   26            1                    0                 3               RT‐PCR/IHC
  BC22     63    2           Yes                     IIIA    Positive   Negative   Negative   90            1                    0                 3               RT‐PCR/IHC
  BC23     46    2           Yes                     IIIA    Positive   Positive   Negative   Unavailable   1                    0                 3               RT‐PCR/IHC
  BC24     62    2           Yes                     IIIC    Positive   Positive   Negative   39            1                    0                 3               RT‐PCR/IHC
  BC25     73    2           Yes                     IIIA    Positive   Positive   Positive   8             1                    0                 1               RT‐PCR/IHC
  BC26     43    4c          Yes                     IIIC    Negative   Negative   Positive   Unavailable   1                    0                 3               RT‐PCR/IHC
  BC27     46    2           Yes                     IIB     Negative   Negative   Positive   35            1                    0                 3               RT‐PCR/IHC
  BC28     70    2           No                      IIA     Negative   Negative   Positive   52            0                    0                 3               RT‐PCR/IHC
  BC29     69    1mi         No                      I       Negative   Negative   Positive   13            0                    0                 1               RT‐PCR/IHC
  BC30     39    2           Yes                     IIIC    Negative   Negative   Positive   35            1                    1                 2               RT‐PCR/IHC
  BC31     59    1b          Yes                     IIA     Negative   Negative   Negative   98            1                    1                 3               RT‐PCR/IHC
  BC32     64    4b          No                      IIIB    Negative   Negative   Negative   50            1                    0                 3               RT‐PCR/IHC
  BC33     65    1c          Yes                     IIA     Negative   Negative   Negative   91            1                    1                 3               RT‐PCR/IHC
  BC34     41    2           Yes                     ⅢC      Negative   Negative   Negative   Unavailable   1                    1                 3               IHC
  BC35     38    1c          No                      Ⅰ       Negative   Negative   Negative   Unavailable   0                    0                 3               IHC
  BC36     39    2           No                      ⅡA      Positive   Positive   Positive   28            0                    0                 1               IHC
  Ｎ１     50                                                                                                                                                      RNA seq.
  Ｎ２     26                                                                                                                                                      RNA seq.
  Ｎ３     62                                                                                                                                                      RNA seq.
  Ｎ４     65                                                                                                                                                      RNA seq.
  Ｎ５     52                                                                                                                                                      RNA seq.
  Ｎ６     79                                                                                                                                                      RT‐PCR
  Ｎ７     38                                                                                                                                                      RT‐PCR
  Ｎ８     85                                                                                                                                                      RT‐PCR
  Ｎ９     44                                                                                                                                                      RT‐PCR
  Ｎ１０   61                                                                                                                                                      RT‐PCR
  Ｎ１１   56                                                                                                                                                      RT‐PCR
  Ｎ１２   69                                                                                                                                                      RT‐PCR
  Ｎ１３   62                                                                                                                                                      RT‐PCR
  Ｎ１４   59                                                                                                                                                      RT‐PCR
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Two BrCa cell lines, i.e. MDA‐MB‐231 and MCF‐7, were used in this study. MDA‐MB‐231 cells (acc. no. 92020424, Lot: 15J060) were obtained from Public Health England (Salisbury, UK). MCF‐7 cells (resource no. RCB1904, Lot: 13) were obtained from RIKEN BRC CELL BANK (Tsukuba, Ibaraki, Japan).

2.2. Construction of the miRNA expression signature for BrCa {#mol212602-sec-0004}
------------------------------------------------------------

The miRNA expression signatures of 20 samples with BrCa (Table [1](#mol212602-tbl-0001){ref-type="table"}) were generated by small RNA sequencing using HiSeq 2000 (Illumina, San Diego, CA, USA). Small RNA sequencing and data mining were performed as previously described, and a false discovery rate (FDR) less than 0.05 was considered significant (Goto *et al.*, [2017](#mol212602-bib-0014){ref-type="ref"}; Koshizuka *et al.*, [2017](#mol212602-bib-0023){ref-type="ref"}; Toda *et al.*, [2018](#mol212602-bib-0050){ref-type="ref"}; Yonemori *et al.*, [2017](#mol212602-bib-0058){ref-type="ref"}).

2.3. RNA preparation and quantitative reverse transcription polymerase chain reaction (qRT‐PCR) {#mol212602-sec-0005}
-----------------------------------------------------------------------------------------------

Total RNA including miRNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) in clinical specimens and ISOGEN reagent (NIPPON GENE, Tokyo, Japan) in BrCa cells. The qRT‐PCR was performed as previously described (Idichi *et al.*, [2018](#mol212602-bib-0018){ref-type="ref"}; Yamada *et al.*, [2018a](#mol212602-bib-0055){ref-type="ref"},[b](#mol212602-bib-0056){ref-type="ref"},[c](#mol212602-bib-0057){ref-type="ref"}). TaqMan probes and primers used in this study are listed in Table [S1](#mol212602-sup-0011){ref-type="supplementary-material"}.

2.4. Transfection of BrCa cells with miRNA, small interfering RNA (siRNA), and plasmid vectors {#mol212602-sec-0006}
----------------------------------------------------------------------------------------------

The miRNA, siRNA, and vectors were transfected into cancer cells as described in our previous reports using the reagents listed in Table [S1](#mol212602-sup-0011){ref-type="supplementary-material"} (Idichi *et al.*, [2018](#mol212602-bib-0018){ref-type="ref"}; Yamada *et al.*, [2018a](#mol212602-bib-0055){ref-type="ref"},[b](#mol212602-bib-0056){ref-type="ref"},[c](#mol212602-bib-0057){ref-type="ref"}).

2.5. Assays of cell proliferation, cell cycle, migration, and invasion {#mol212602-sec-0007}
----------------------------------------------------------------------

Cell proliferation, migration, and invasion were assessed as described previously (Idichi *et al.*, [2018](#mol212602-bib-0018){ref-type="ref"}; Yamada *et al.*, [2018a](#mol212602-bib-0055){ref-type="ref"},[b](#mol212602-bib-0056){ref-type="ref"},[c](#mol212602-bib-0057){ref-type="ref"}).

2.6. Assay of *miR‐101‐5p* incorporation into the RNA‐induced silencing complex (RISC) {#mol212602-sec-0008}
--------------------------------------------------------------------------------------

MDA‐MB‐231 cells were transfected with 10 n[m]{.smallcaps} control miRNA, *miR‐101‐5p*, or *miR‐101‐3p*. After 72 h, miRNA incorporated into the RISC were isolated using a human *AGO2* miRNA isolation kit (Wako Pure Chemical Industries, Ltd., Osaka, Japan). Expression *miR‐101‐5p* was examined as described above (Idichi *et al.*, [2018](#mol212602-bib-0018){ref-type="ref"}; Yamada *et al.*, [2018a](#mol212602-bib-0055){ref-type="ref"},[b](#mol212602-bib-0056){ref-type="ref"},[c](#mol212602-bib-0057){ref-type="ref"}).

2.7. Isolation of putative oncogenic targets regulated by *miR‐101‐5p* in BrCa cells {#mol212602-sec-0009}
------------------------------------------------------------------------------------

Putative target genes possessing binding sequences to *miR‐101‐5p* were isolated using the TargetScan Human database ver.7.1 (<http://www.targetscan.org/vert_71/>). Gene expression data (protein‐coding RNAs) for BrCa clinical specimens were obtained by oligo‐microarray analyses.

2.8. Evaluation of *miR‐101‐5p* binding sites by luciferase reporter assays {#mol212602-sec-0010}
---------------------------------------------------------------------------

The 3′ UTR of *GINS1* and the 3′‐UTR lacking the putative *miR‐101‐5p* binding sites were cloned into the psiCHECK‐2 vector (C8021; Promega, Madison, WI, USA). Luciferase reporter assays were performed as previously described (Idichi *et al.*, [2018](#mol212602-bib-0018){ref-type="ref"}; Yamada *et al.*, [2018a](#mol212602-bib-0055){ref-type="ref"},[b](#mol212602-bib-0056){ref-type="ref"},[c](#mol212602-bib-0057){ref-type="ref"}). The cloned sequences are shown in Figs [4](#mol212602-fig-0004){ref-type="fig"} and S1.

2.9. Clinical data analyses of BrCa {#mol212602-sec-0011}
-----------------------------------

The clinical significance of miRNA and their target genes was investigated with The Cancer Genome Atlas (TCGA; <https://tcga-data.nci.nih.gov/tcga/>) in BrCa. Gene expression levels and clinical information obtained from cBioPortal (<http://www.cbioportal.org/>) and OncoLnc (<http://www.oncolnc.org/>) were applied. The data were downloaded on 28 September 2018.

2.10. Western blotting and immunohistochemistry {#mol212602-sec-0012}
-----------------------------------------------

Western blotting and immunohistochemistry were performed as described previously (Idichi *et al.*, [2018](#mol212602-bib-0018){ref-type="ref"}; Yamada *et al.*, [2018a](#mol212602-bib-0055){ref-type="ref"},[b](#mol212602-bib-0056){ref-type="ref"},[c](#mol212602-bib-0057){ref-type="ref"}). Primary antibodies are listed in Table [S1](#mol212602-sup-0011){ref-type="supplementary-material"}.

2.11. Genes affected by *GINS1* expression in BrCa cells {#mol212602-sec-0013}
--------------------------------------------------------

Gene expression levels and clinical information were downloaded from cBioPortal (<http://www.cbioportal.org/>) on 8 January 2019. The normalized mRNA expression levels of RNA‐sequencing data were provided as *Z*‐scores. Gene set enrichment analysis (GSEA) was performed based on mRNA sequence data from cBioPortal. A heatmap of gene expression was constructed using the BrCa RNA‐sequence database. Overexpressed genes in BrCa tissues showing high *GINS1* expression in TCGA were classified into known pathways using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database with the Enrichr program.

2.12. Statistical analysis {#mol212602-sec-0014}
--------------------------

Mann--Whitney *U* tests were applied for comparisons between two groups. For multiple groups, one‐way analysis of variance and Tukey tests for post‐hoc analysis were applied. These analyses were performed with [graphpad prism 7]{.smallcaps} (GraphPad Software, La Jolla, CA, USA) and [jmp pro]{.smallcaps} 14 (SAS Institute Inc., Cary, NC, USA). For other analyses,[expert statview]{.smallcaps} (version 5, SAS Institute, Inc.) was used.

3. Results {#mol212602-sec-0015}
==========

3.1. Creation of a miRNA expression signature for BrCa by small RNA sequencing {#mol212602-sec-0016}
------------------------------------------------------------------------------

RNA sequencing was performed to create the miRNA expression signature of BrCa. We sequenced 20 small RNA libraries (15 BrCa specimens and five normal breast epithelium specimens). The clinical features of the specimens used to create the miRNA signature are summarized in Table [1](#mol212602-tbl-0001){ref-type="table"}.

We obtained between 10 112 255 and 15 495 422 total reads in this study. After filtering out noise (fragments that did not completely match the human genome sequence), between 4 781 591 and 13 003 597 miRNA reads were mapped on the human genome sequence (Table [S2](#mol212602-sup-0012){ref-type="supplementary-material"}). Read sequences matching the human genome were categorized into small RNA according to their biological functions (Table [S2](#mol212602-sup-0012){ref-type="supplementary-material"}). Finally, we constructed the miRNA expression signature of BrCa containing miRNA with markedly downregulated expression (Table [2](#mol212602-tbl-0002){ref-type="table"}; FDR \< 0.05).

###### 

Downregulated miRNA in BrCa compared with normal breast.

+---------------------+-------------------+----------+----------+-----------+----------+
| miRNA               | miRBase accession | Location | Log~2~FC | *P*‐value | FDR      |
+=====================+===================+==========+==========+===========+==========+
| *hsa‐miR‐204‐5p*    | *MIMAT0000265*    | 9q21.12  | −4.6141  | 2.58E‐12  | 9.51E‐10 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐551b‐3p*   | *MIMAT0003233*    | 3q26.2   | −4.0638  | 7.63E‐13  | 3.93E‐10 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐139‐5p*    | *MIMAT0000250*    | 11q13.4  | −3.9735  | 3.64E‐24  | 9.38E‐21 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐378i*      | *MI0016902*       | 22q13.2  | −3.8250  | 9.48E‐07  | 6.60E‐05 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐422a*      | *MI0001444*       | 15q22.31 | −3.8117  | 2.10E‐07  | 1.80E‐05 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐451a*      | *MI0001729*       | 17q11.2  | −3.6452  | 2.03E‐12  | 8.73E‐10 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐144‐3p*    | *MIMAT0000436*    | 17q11.2  | −3.5713  | 2.86E‐10  | 6.69E‐08 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐4703‐3p*   | *MIMAT0019802*    | 13q14.3  | −3.5033  | 1.47E‐05  | 6.37E‐04 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐144‐5p*    | *MIMAT0004600*    | 17q11.2  | −3.4272  | 2.24E‐09  | 3.21E‐07 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐891a‐5p*   | *MIMAT0004902*    | Xq27.3   | −3.3293  | 8.14E‐06  | 4.20E‐04 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐335‐5p*    | *MIMAT0000765*    | 7q32.2   | −3.1273  | 8.99E‐09  | 9.65E‐07 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐99a‐5p*    | *MIMAT0000097*    | 21q21.1  | −3.0151  | 3.80E‐12  | 1.22E‐09 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐376c‐5p*   | *MIMAT0022861*    | 14q32.31 | −2.9571  | 4.66E‐04  | 1.13E‐02 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐486‐5p*    | *MIMAT0002177*    | 8p11.21  | −2.9506  | 2.38E‐11  | 6.83E‐09 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐944*       | *MI0005769*       | 3q28     | −2.9246  | 1.17E‐07  | 1.04E‐05 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐376b‐5p*   | *MIMAT0022923*    | 14q32.31 | −2.8728  | 7.38E‐04  | 1.64E‐02 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐655‐3p*    | *MIMAT0003331*    | 14q32.31 | −2.8446  | 8.96E‐08  | 8.24E‐06 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐139‐3p*    | *MIMAT0004552*    | 11q13.4  | −2.7660  | 1.69E‐04  | 4.93E‐03 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐585‐3p*    | *MIMAT0003250*    | 5q35.1   | −2.7236  | 3.02E‐05  | 1.16E‐03 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐224‐3p*    | *MIMAT0009198*    | Xq28     | −2.6844  | 3.98E‐05  | 1.51E‐03 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐4510*      | *MI0016876*       | 15q14    | −2.6373  | 7.56E‐05  | 2.53E‐03 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐202‐5p*    | *MIMAT0002810*    | 10q26.3  | −2.5628  | 4.56E‐04  | 1.12E‐02 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐483‐3p*    | *MIMAT0002173*    | 11p15.5  | −2.5243  | 4.82E‐05  | 1.77E‐03 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐215‐5p*    | *MIMAT0000272*    | 1q41     | −2.5094  | 1.23E‐08  | 1.26E‐06 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐99a‐3p*    | *MIMAT0004511*    | 21q21.1  | −2.4961  | 4.85E‐08  | 4.63E‐06 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐126‐5p*    | *MIMAT0000444*    | 9q34.3   | −2.4707  | 3.72E‐16  | 4.79E‐13 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐452‐5p*    | *MIMAT0001635*    | Xq28     | −2.3667  | 8.31E‐04  | 1.80E‐02 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐488‐3p*    | *MIMAT0004763*    | 1q25.2   | −2.3654  | 1.12E‐03  | 2.33E‐02 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐10b‐5p*    | *MIMAT0000254*    | 2q31.1   | −2.3495  | 1.11E‐05  | 5.21E‐04 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐100‐5p*    | *MIMAT0000098*    | 11q24.1  | −2.3427  | 1.27E‐06  | 8.40E‐05 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐133a‐3p*   | *MIMAT0000427*    | 18q11.2  | −2.3206  | 5.81E‐07  | 4.15E‐05 |
|                     |                   |          |          |           |          |
|                     |                   | 20q13.33 |          |           |          |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐130a‐5p*   | *MIMAT0004593*    | 11q12.1  | −2.3094  | 1.26E‐03  | 2.59E‐02 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐let‐7c‐5p*     | *MIMAT0000064*    | 21q21.1  | −2.2647  | 4.27E‐07  | 3.24E‐05 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐10b‐3p*    | *MIMAT0004556*    | 2q31.1   | −2.2553  | 1.87E‐09  | 3.01E‐07 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐5683*      | *MI0019284*       | 6p25.1   | −2.1729  | 9.01E‐04  | 1.92E‐02 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐101‐5p*    | *MIMAT0004513*    | 1p31.3   | −2.1712  | 2.44E‐10  | 6.29E‐08 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐195‐5p*    | *MIMAT0000461*    | 17p13.1  | −2.0969  | 3.65E‐08  | 3.62E‐06 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐19b‐3p*    | *MIMAT0000074*    | 13q31.3  | −2.0345  | 1.87E‐05  | 7.76E‐04 |
|                     |                   |          |          |           |          |
|                     |                   | Xq26.2   |          |           |          |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐145‐3p*    | *MIMAT0004601*    | 5q32     | −1.9876  | 8.16E‐09  | 9.37E‐07 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐378a‐5p*   | *MIMAT0000731*    | 5q32     | −1.9654  | 2.36E‐05  | 9.51E‐04 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐377‐5p*    | *MIMAT0004689*    | 14q32.31 | −1.9470  | 9.03E‐04  | 1.92E‐02 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐193a‐3p*   | *MIMAT0000459*    | 17q11.2  | −1.9030  | 1.24E‐05  | 5.50E‐04 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐125b‐2‐3p* | *MIMAT0004603*    | 21q21.1  | −1.8634  | 1.90E‐05  | 7.76E‐04 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐376c‐3p*   | *MIMAT0000720*    | 14q32.31 | −1.8379  | 2.69E‐04  | 7.15E‐03 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐130a‐3p*   | *MIMAT0000425*    | 11q12.1  | −1.8198  | 1.61E‐05  | 6.78E‐04 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐378a‐3p*   | *MIMAT0000732*    | 5q32     | −1.7951  | 7.20E‐04  | 1.61E‐02 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐26a‐5p*    | *MIMAT0000082*    | 3p22.2   | −1.7197  | 1.21E‐04  | 3.72E‐03 |
|                     |                   |          |          |           |          |
|                     |                   | 12q14.1  |          |           |          |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐497‐5p*    | *MIMAT0002820*    | 17p13.1  | −1.7189  | 8.34E‐06  | 4.21E‐04 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐126‐3p*    | *MIMAT0000445*    | 9q34.3   | −1.7138  | 1.48E‐05  | 6.37E‐04 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐154‐5p*    | *MIMAT0000452*    | 14q32.31 | −1.6895  | 7.67E‐04  | 1.69E‐02 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐376a‐3p*   | *MIMAT0000729*    | 14q32.31 | −1.6814  | 1.73E‐03  | 3.33E‐02 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐136‐3p*    | *MIMAT0004606*    | 14q32.2  | −1.5735  | 3.54E‐04  | 9.02E‐03 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐218‐5p*    | *MIMAT0000275*    | 4p15.31  | −1.5112  | 1.13E‐05  | 5.22E‐04 |
|                     |                   |          |          |           |          |
|                     |                   | 5q34     |          |           |          |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐299‐3p*    | *MIMAT0000687*    | 14q32.31 | −1.4961  | 5.46E‐04  | 1.28E‐02 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐143‐3p*    | *MIMAT0000435*    | 5q32     | −1.4679  | 2.10E‐04  | 5.94E‐03 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐143‐5p*    | *MIMAT0004599*    | 5q32     | −1.4443  | 2.24E‐04  | 6.20E‐03 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐152‐3p*    | *MIMAT0000438*    | 17q21.32 | −1.4362  | 4.80E‐05  | 1.77E‐03 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐101‐3p*    | *MIMAT0000099*    | 1p31.3   | −1.3746  | 1.51E‐06  | 9.59E‐05 |
|                     |                   |          |          |           |          |
|                     |                   | 9p24.1   |          |           |          |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐195‐3p*    | *MIMAT0004615*    | 17p13.1  | −1.3699  | 3.85E‐04  | 9.62E‐03 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐30e‐3p*    | *MIMAT0000693*    | 1p34.2   | −1.3396  | 5.65E‐07  | 4.15E‐05 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐424‐5p*    | *MIMAT0001341*    | Xq26.3   | −1.3074  | 2.40E‐03  | 4.45E‐02 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐574‐3p*    | *MIMAT0003239*    | 4p14     | −1.2822  | 7.99E‐05  | 2.64E‐03 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐let‐7g‐3p*     | *MIMAT0004584*    | 3p21.2   | −1.0676  | 2.29E‐03  | 4.31E‐02 |
+---------------------+-------------------+----------+----------+-----------+----------+
| *hsa‐miR‐374a‐5p*   | *MIMAT0000727*    | Xq13.2   | −1.0478  | 3.51E‐04  | 9.02E‐03 |
+---------------------+-------------------+----------+----------+-----------+----------+
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In total, 64 miRNA were significantly downregulated in BrCa tissues (Table [2](#mol212602-tbl-0002){ref-type="table"}). Analysis of our BrCa signature revealed that 11 miRNA duplexes (guide strand/passenger strand) derived from pre‐miRNA were downregulated in BrCa tissues (Table [S3](#mol212602-sup-0013){ref-type="supplementary-material"}).

3.2. Expression levels of both strands of the *miR‐101* duplex (*miR‐101‐5p* and *miR‐101‐3p*) in BrCa tissues and cell lines {#mol212602-sec-0017}
-----------------------------------------------------------------------------------------------------------------------------

In the human genome, pre‐*miR‐101* is located at two chromosomal loci, pre‐*miR‐101‐1* (1p31.3) and pre‐*miR‐101‐2* (9q24.1; Fig. S2). In this study, we focused on *miR‐101‐1‐5p* (mature sequence: 5′‐caguuaucacagugcugaugcu‐3′) and *miR‐101‐3p* (5′‐uacaguacugugauaacugaa‐3′). According to the TargetScan database, *miR‐101‐5p* is the passenger strand (minor strand), whereas *miR‐101‐3p* is the guide strand (major strand).

To verify the credibility of the BrCa signature, expression levels of *miR‐101‐5p* and *miR‐101‐3p* in clinical specimens (18 BrCa specimens and nine normal breast epithelial specimens) and two cell lines (MDA‐MB‐231 and MCF‐7) were measured. Table [1](#mol212602-tbl-0001){ref-type="table"} shows the information on the clinical specimens used for this study. The expression levels of the two miRNA, i.e. *miR‐101‐5p* (*P* = 0.0396) and *miR‐101‐3p* (*P* = 0.0047), were significantly reduced in BrCa tissues (Fig. [1](#mol212602-fig-0001){ref-type="fig"}A,B). Moreover, we confirmed that the expression levels were low in the two cell lines (Fig. [1](#mol212602-fig-0001){ref-type="fig"}A,B).

![The clinical significance of *miR‐101‐5p* and *miR‐101‐3p* expression in BrCa. (A,B) Downregulation of *miR‐101‐5p* and *miR‐101‐3p* expression in BrCa specimens and two cell lines (MDA‐MB‐231 and MCF‐7). Expression of *RNU48* was used as an internal control. (C,D) Kaplan--Meier overall survival curve analyses of patients with BrCa using data from TCGA database. Patients were divided into two groups according to miRNA expression and analyzed. (E--G) Functional assays of *miR‐101‐5p* and *miR‐101‐3p* in BrCa cells (MDA‐MB‐231 and MCF‐7). Cell proliferation, migration, and invasion were significantly blocked by ectopic expression of *miR‐101‐5p* or *miR‐101‐3p*. Error bars are represented as mean ± SD. *P*‐values were calculated using Bonferroni‐adjusted Mann‐Whitney *U*‐test. \**P* \< 0.01, \*\**P* \< 0.0001.](MOL2-14-426-g001){#mol212602-fig-0001}

Next, we analyzed whether miRNA expression affected the prognosis of patients with BrCa by TCGA database analysis. Kaplan--Meier overall survival curves showed that low expression levels of *miR‐101‐5p* (*P* = 0.0316) and *miR‐101‐3p* (*P* = 0.0280) were associated with overall survival in patients with BrCa (Fig. [1](#mol212602-fig-0001){ref-type="fig"}C,D).

3.3. Expression of *miR‐101‐5p* and *miR‐101‐3p* inhibited the aggressive phenotypes of BrCa cells {#mol212602-sec-0018}
--------------------------------------------------------------------------------------------------

To verify that *miR‐101‐3p* and *miR‐101‐5p* had tumor‐suppressor functions in BrCa cells, we performed ectopic expression assays using mature miRNA transfection into BrCa cell lines (MDA‐MB‐231 and MCF‐7). Cell proliferation assays showed that *miR‐101‐5p*‐ and *miR‐101‐3p*‐transfected BrCa cells exhibited reduced cell growth compared with miR‐control‐transfected BrCa cells (Fig. [1](#mol212602-fig-0001){ref-type="fig"}E). We also performed cell cycle assays to determine the effects of *miR‐101‐5p* expression. Our data showed that G~0~/G~1~ phase arrest was observed following *miR‐101‐5p* expression in MDA‐MB‐231 cells (Fig. S3).

Additionally, cell migratory and invasive abilities were markedly attenuated in cells transfected with *miR‐101‐5p* and *miR‐101‐3p* (Fig. [1](#mol212602-fig-0001){ref-type="fig"}F,G).

3.4. *MicroR‐101‐5p* was incorporated into the RNA‐induced silencing complex (RISC) in BrCa cells {#mol212602-sec-0019}
-------------------------------------------------------------------------------------------------

Next, we aimed to verify that *miR‐101‐5p* (passenger strand) had actual functions in BrCa cells. It is essential that miRNA are incorporated into the RISC to control target genes. Ago2 is a fundamental component of the RISC. Therefore, immunoprecipitation using anti‐Ago2 antibodies was performed after transfection of *miR‐101‐5p* into MDA‐MB‐231 cells. The amount of *miR‐101‐5p* incorporated into the protein was measured by PCR. Levels of *miR‐101‐5p* in the immunoprecipitates were much higher than those in mock‐, miR‐control‐ or *miR‐101‐3p*‐transfected cells (*P* \< 0.0001; Fig. S4).

3.5. Candidate oncogenic targets regulated by *miR‐101‐5p* in BrCa cells {#mol212602-sec-0020}
------------------------------------------------------------------------

The TargetScan Human 7.1 database predicted that 2896 candidate genes had *miR‐101‐5p* binding sites in the 3′‐UTR. We also investigated genes that were upregulated in clinical BrCa specimens by microarray analysis \[Gene Expression Omnibus (GEO) accession number: <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118539>\] and compiled a list of 1121 genes. Finally, 104 oncogenic targets regulated by *miR‐101‐5p* were identified in BrCa cells (Table [3](#mol212602-tbl-0003){ref-type="table"}). Our selection strategy for *miR‐101‐5p* targets is shown in Fig. S5.

###### 

Identification of target genes (TargetScan + Upregulated mRNA FC \> 1.5).

+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| Gene Symbol | Ensembl ID      | Gene name                                                                                            | Total sites | Fold change |
+=============+=================+======================================================================================================+=============+=============+
| HIST1H2AG   | ENST00000359193 | Histone cluster 1, H2ag                                                                              | 2           | 5.561       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| PBK         | ENST00000301905 | PDZ binding kinase                                                                                   | 2           | 4.654       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| SPP1        | ENST00000360804 | Secreted phosphoprotein 1                                                                            | 1           | 4.244       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| CXCL9       | ENST00000264888 | Chemokine (C‐X‐C motif) ligand 9                                                                     | 1           | 3.895       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| LMNB1       | ENST00000460265 | Lamin B1                                                                                             | 1           | 3.826       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| GINS1       | ENST00000262460 | *GINS1* (Psf1 homolog)                                                                               | 1           | 3.790       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| HMGB3       | ENST00000325307 | High Mobility Group Box 3                                                                            | 1           | 3.380       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| SBK1        | ENST00000341901 | SH3 domain binding kinase 1                                                                          | 1           | 3.313       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| LRP8        | ENST00000306052 | Low density lipoprotein receptor‐related protein 8, apolipoprotein e receptor                        | 1           | 3.285       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| TRIM59      | ENST00000309784 | Tripartite motif containing 59                                                                       | 1           | 3.124       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| ESRP1       | ENST00000517556 | Epithelial Splicing Regulatory Protein 1                                                             | 1           | 3.081       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| ESPL1       | ENST00000552462 | Extra spindle pole bodies homolog 1 (*Saccharomyces cerevisiae*)                                     | 1           | 3.080       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| MAD2L1      | ENST00000504707 | MAD2 mitotic arrest deficient‐like 1 (yeast)                                                         | 1           | 2.994       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| ATAD2       | ENST00000287394 | ATPase family, AAA domain containing 2                                                               | 3           | 2.722       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| SELL        | ENST00000236147 | Selectin L                                                                                           | 1           | 2.633       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| COL5A1      | ENST00000618395 | Collagen, type V, alpha 1                                                                            | 1           | 2.519       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| PARPBP      | ENST00000327680 | PARP1 binding protein                                                                                | 1           | 2.472       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| TFEC        | ENST00000393485 | Transcription factor EC                                                                              | 3           | 2.459       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| PMAIP1      | ENST00000316660 | Phorbol‐12‐myristate‐13‐acetate‐induced protein 1                                                    | 1           | 2.425       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| SLC7A11     | ENST00000280612 | Solute carrier family 7 (anionic amino acid transporter light chain, xc‐ system), member 11          | 2           | 2.399       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| SLC37A2     | ENST00000526405 | Solute carrier family 37 (glucose‐6‐phosphate transporter), member 2                                 | 1           | 2.390       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| HIST2H4B    | ENST00000578186 | Histone cluster 2, H4b                                                                               | 2           | 2.370       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| DONSON      | ENST00000442660 | Downstream neighbor of SON                                                                           | 1           | 2.336       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| LAX1        | ENST00000442561 | Lymphocyte transmembrane adaptor 1                                                                   | 2           | 2.326       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| LILRB1      | ENST00000421584 | Leukocyte immunoglobulin‐like receptor, subfamily B (with TM and ITIM domains), member 1             | 1           | 2.318       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| PNP         | ENST00000554056 | Purine nucleoside phosphorylase                                                                      | 1           | 2.318       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| PAG1        | ENST00000220597 | Phosphoprotein associated with glycosphingolipid microdomains 1                                      | 1           | 2.316       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| CHML        | ENST00000366553 | Choroideremia‐like (Rab escort protein 2)                                                            | 3           | 2.312       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| HIST1H2AH   |                 | 0 histone cluster 1, H2ah                                                                            | 1           | 2.312       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| DIO2        | ENST00000557010 | Deiodinase, iodothyronine, type II                                                                   | 1           | 2.278       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| ASPN        | ENST00000375544 | asporin                                                                                              | 1           | 2.249       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| CXADR       | ENST00000400165 | Coxsackie virus and adenovirus receptor                                                              | 1           | 2.248       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| IFI44L      | ENST00000476521 | Interferon‐induced protein 44‐like                                                                   | 1           | 2.222       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| KNTC1       | ENST00000333479 | Kinetochore associated 1                                                                             | 1           | 2.221       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| HELLS       | ENST00000394036 | Helicase, lymphoid‐specific                                                                          | 1           | 2.214       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| MTL5        | ENST00000255087 | Metallothionein‐like 5, testis‐specific (tesmin)                                                     | 1           | 2.201       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| CXCR6       | ENST00000438735 | Chemokine (C‐X‐C motif) receptor 6                                                                   | 1           | 2.189       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| ADAM12      | ENST00000368679 | ADAM metallopeptidase domain 12                                                                      | 1           | 2.174       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| LILRB2      | ENST00000493242 | Leukocyte immunoglobulin‐like receptor, subfamily B (with TM and ITIM domains), member 2             | 1           | 2.141       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| ITGA4       | ENST00000614742 | Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA‐4 receptor)                                 | 1           | 2.127       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| TMEM97      | ENST00000226230 | Transmembrane protein 97                                                                             | 1           | 2.121       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| HIST1H2AK   | ENST00000618958 | Histone cluster 1, H2ak                                                                              | 1           | 2.118       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| FAM84A      | ENST00000331243 | Family with sequence similarity 84, member A                                                         | 1           | 2.089       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| CKAP2       | ENST00000258607 | cytoskeleton associated protein 2                                                                    | 2           | 2.000       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| PTPRC       | ENST00000442510 | Protein tyrosine phosphatase, receptor type, C                                                       | 1           | 1.989       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| IGSF6       | ENST00000268389 | Immunoglobulin superfamily, member 6                                                                 | 1           | 1.988       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| TPD52       | ENST00000448733 | Tumor Protein D52                                                                                    | 1           | 1.958       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| SLC20A1     | ENST00000490674 | Solute carrier family 20 (phosphate transporter), member 1                                           | 1           | 1.934       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| LCP2        | ENST00000520322 | Lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76kDa)                    | 1           | 1.926       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| OCIAD2      | ENST00000381464 | OCIA domain containing 2                                                                             | 1           | 1.926       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| SLC17A9     | ENST00000488738 | Solute carrier family 17 (vesicular nucleotide transporter), member 9                                | 1           | 1.896       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| SSTR2       | ENST00000357585 | Somatostatin receptor 2                                                                              | 2           | 1.894       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| NLRC3       | ENST00000615877 | NLR family, CARD domain containing 3                                                                 | 1           | 1.874       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| VANGL1      | ENST00000310260 | VANGL planar cell polarity protein 1                                                                 | 1           | 1.861       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| ZFP69B      | ENST00000469416 | ZFP69 zinc finger protein B                                                                          | 2           | 1.848       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| CEACAM7     | ENST00000006724 | Carcinoembryonic antigen‐related cell adhesion molecule 7                                            | 1           | 1.846       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| SORD        | ENST00000562107 | Sorbitol dehydrogenase                                                                               | 2           | 1.844       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| AARD        | ENST00000378279 | Alanine‐ and arginine‐rich domain containing protein                                                 | 2           | 1.830       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| MMS22L      | ENST00000275053 | MMS22‐like, DNA repair protein                                                                       | 2           | 1.824       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| ANGPT2      | ENST00000325203 | Angiopoietin 2                                                                                       | 1           | 1.824       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| NCAPG2      | ENST00000467785 | Non‐SMC condensin II complex, subunit G2                                                             | 1           | 1.804       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| HIST1H2BN   | ENST00000396980 | Histone cluster 1, H2bn                                                                              | 1           | 1.790       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| CENPW       | ENST00000368325 | Centromere protein W                                                                                 | 2           | 1.790       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| IFI44       | ENST00000485662 | Interferon‐induced protein 44                                                                        | 1           | 1.779       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| KCNE4       | ENST00000281830 | Potassium voltage‐gated channel, Isk‐related family, member 4                                        | 1           | 1.776       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| MGAT4A      | ENST00000409391 | Mannosyl (alpha‐1,3‐)‐glycoprotein beta‐1,4‐*N*‐acetylglucosaminyltransferase, isozyme A             | 2           | 1.770       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| TAGAP       | ENST00000326965 | T‐cell activation RhoGTPase activating protein                                                       | 1           | 1.760       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| FYB         | ENST00000351578 | FYN binding protein                                                                                  | 1           | 1.748       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| CD84        | ENST00000368047 | CD84 molecule                                                                                        | 1           | 1.746       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| AMMECR1     | ENST00000262844 | Alport syndrome, mental retardation, midface hypoplasia and elliptocytosis chromosomal region gene 1 | 2           | 1.740       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| CYTIP       | ENST00000264192 | Cytohesin 1‐interacting protein                                                                      | 2           | 1.734       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| SKA2        | ENST00000583976 | Spindle and kinetochore associated complex subunit 2                                                 | 3           | 1.706       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| ANP32E      | ENST00000436748 | Acidic (leucine‐rich) nuclear phosphoprotein 32 family, member E                                     | 1           | 1.706       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| FAM83B      | ENST00000306858 | Family with sequence similarity 83, member B                                                         | 1           | 1.702       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| BCL3        | ENST00000164227 | B‐cell CLL/lymphoma 3                                                                                | 1           | 1.701       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| HEYL        | ENST00000372852 | Hairy/enhancer‐of‐split related with YRPW motif‐like                                                 | 1           | 1.691       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| BORA        | ENST00000613797 | Bora, aurora kinase A activator                                                                      | 1           | 1.658       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| FAXC        | ENST00000389677 | Failed axon connections homolog (*Drosophila*)                                                       | 1           | 1.657       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| PRKDC       | ENST00000338368 | protein kinase, DNA‐activated, catalytic polypeptide                                                 | 1           | 1.643       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| SFMBT1      | ENST00000394752 | Scm‐like with four mbt domains 1                                                                     | 1           | 1.639       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| CCRL2       | ENST00000400882 | Chemokine (C‐C motif) receptor‐like 2                                                                | 1           | 1.636       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| GEN1        | ENST00000381254 | GEN1 Holliday junction 5\' flap endonuclease                                                         | 1           | 1.629       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| MSH2        | ENST00000543555 | mutS homolog 2                                                                                       | 1           | 1.623       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| SLC22A15    | ENST00000369503 | Solute carrier family 22, member 15                                                                  | 1           | 1.615       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| TMEM154     | ENST00000304385 | Transmembrane protein 154                                                                            | 2           | 1.592       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| MAGOHB      | ENST00000537852 | Mago‐nashi homolog B (*Drosophila*)                                                                  | 1           | 1.583       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| AK2         | ENST00000373449 | Adenylate kinase 2                                                                                   | 1           | 1.577       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| USB1        |                 | 0 U6 snRNA biogenesis 1                                                                              | 1           | 1.577       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| IL10RA      | ENST00000227752 | Interleukin 10 receptor, alpha                                                                       | 1           | 1.575       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| FAM122B     | ENST00000465128 | Family with sequence similarity 122B                                                                 | 1           | 1.574       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| TRPV2       | ENST00000338560 | transient receptor potential cation channel, subfamily V, member 2                                   | 2           | 1.559       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| XRCC3       | ENST00000554811 | X‐ray repair complementing defective repair in Chinese                                               | 1           | 1.556       |
|             |                 |                                                                                                      |             |             |
|             |                 | hamster cells 3                                                                                      |             |             |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| KCTD5       | ENST00000301738 | Potassium channel tetramerization domain containing 5                                                | 1           | 1.550       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| MYCBP       | ENST00000465771 | MYC binding protein                                                                                  | 1           | 1.548       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| NDC1        | ENST00000371429 | NDC1 transmembrane nucleoporin                                                                       | 2           | 1.545       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| SRPK1       | ENST00000373822 | SRSF protein kinase 1                                                                                | 1           | 1.532       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| FGFR1OP     | ENST00000349556 | FGFR1 oncogene partner                                                                               | 1           | 1.531       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| PRPS2       | ENST00000380668 | Phosphoribosyl pyrophosphate synthetase 2                                                            | 1           | 1.529       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| TNFSF13B    | ENST00000486502 | tumor necrosis factor (ligand) superfamily, member 13b                                               | 2           | 1.527       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| SLC36A1     | ENST00000243389 | solute carrier family 36 (proton/amino acid symporter), member 1                                     | 1           | 1.526       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| CBX3        | ENST00000481057 | Chromobox homolog 3                                                                                  | 1           | 1.516       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| EPT1        | ENST00000613142 | ethanolaminephosphotransferase 1 (CDP‐ethanolamine‐specific)                                         | 3           | 1.516       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| CD300E      | ENST00000392619 | CD300e molecule                                                                                      | 1           | 1.510       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
| WHSC1       | ENST00000312087 | Wolf‐Hirschhorn syndrome candidate 1                                                                 | 2           | 1.510       |
+-------------+-----------------+------------------------------------------------------------------------------------------------------+-------------+-------------+
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Next, we examined the relationship between the pathogenesis of BrCa and these targets using TCGA database. Among 104 targets, seven genes \[High Mobility Group Box 3 (*HMGB3*): *P* = 0.0013, Epithelial splicing regulatory protein 1 (*ESRP1*): *P* = 0.0013, *GINS1*: *P* = 0.0126, Tumor Protein D52 (*TPD52*): *P* = 0.0223, Serine/Arginine‐Rich Splicing Factor Kinase 1 (*SRPK1*): *P* = 0.0225, Vang‐like protein 1 (*VANGL1*): *P* = 0.0447, and Mago Homolog B (*MAGOHB*): *P* = 0.0471\] were significantly associated with poor prognosis in patients with BrCa (Fig. [2](#mol212602-fig-0002){ref-type="fig"}).

![Relationship between the expression levels of seven genes (*HMGB3*, *ESRP1*, *GINS1*, *TPD52*, *SRPK1*, *VANGL1*, and *MAGOHB*) and clinical significance based on data from TCGA database. The Kaplan--Meier overall survival curve analyses of patients with BrCa using data from TCGA database. Patients were divided into two groups according to gene expression and analyzed.](MOL2-14-426-g002){#mol212602-fig-0002}

Moreover, we confirmed that three genes (i.e. *GINS1*, *TPD52*, and *SRPK1*) were significantly downregulated by *miR‐101‐5p* transfection into both MDA‐MB‐231 and MCF‐7 cells (Fig. [3](#mol212602-fig-0003){ref-type="fig"}). These three genes are essential for biological analysis of BrCa cells. We further analyzed the oncogenic functions of *GINS1* in BrCa cells because this gene has not been described frequently in studies of cancer.

![Regulation of seven genes (*HMGB3*, *ESRP1*, *GINS1*, *TPD52*, *SRPK1*, *VANGL1*, and *MAGOHB*) by *miR‐101‐5p* transfection in BrCa cells (MDA‐MB‐231 and MCF‐7). Expression levels of seven genes were evaluated by qRT‐PCR (72 h after *miR‐101‐5p* transfection). *GUSB* was used as a loading control. Error bars are represented as mean ± SD. *P*‐values were calculated using Bonferroni‐adjusted Mann‐Whitney *U*‐test. \**P* \< 0.01.](MOL2-14-426-g003){#mol212602-fig-0003}

3.6. Direct regulation of *GINS1* by *miR‐101‐5p* in BrCa cells {#mol212602-sec-0021}
---------------------------------------------------------------

Expression levels of *GINS1* mRNA and GINS1 protein were significantly reduced by *miR‐101‐5p* transfection (Figs [3](#mol212602-fig-0003){ref-type="fig"} and [4](#mol212602-fig-0004){ref-type="fig"}A).

TargetScan database analysis showed that one putative *miR‐101‐5p* binding site was present in the 3′‐UTR of *GINS1* (Figs [4](#mol212602-fig-0004){ref-type="fig"}B and Fig. S1). Additionally, luciferase reporter assays showed that the luminescence intensity was markedly decreased by cotransfection with *miR‐101‐5p* and a vector carrying wild‐type *GINS1* 3′‐UTR. In contrast, the vector with a deleted *miR‐101‐5p* target site showed no change in luminescence intensity (Fig. [4](#mol212602-fig-0004){ref-type="fig"}C). These data indicated that *GINS1* was directly regulated by *miR‐101‐5p* in BrCa cells.

![Direct regulation of *GINS1* by *miR‐101‐5p* in BrCa cells. (A) Downregulation of *GINS1* protein 72 h after transfection with *miR‐101‐5p* in BrCa cells (MDA‐MB‐231 and MCF‐7). GAPDH was used as a loading control. (B) *miR‐101‐5p* binding site in the 3\'‐UTR of *GINS1* mRNA. (C) Dual luciferase reporter assays using vectors encoding the wild‐type or mutant *miR‐101‐5p* target site in the *GINS1* 3\'‐UTR. Renilla luciferase values were normalized to firefly luciferase values. Error bars are represented as mean ± SD. *P*‐values were calculated using Bonferroni‐adjusted Mann‐Whitney *U*‐test. \**P* \< 0.0001.](MOL2-14-426-g004){#mol212602-fig-0004}

We also investigated the direct regulation of *TPD52* and *SRPK1* by *miR‐101‐5p* in BrCa cells. The luminescence intensities were significantly reduced by cotransfection with *miR‐101‐5p* and vectors carrying wild‐type *TPD52* and *SRPK1* 3′‐UTR, suggesting that these two genes were directly regulated by *miR‐101‐5p* (Fig. S6).

3.7. Expression and clinical significance of *GINS1*/GINS1 in BrCa specimens {#mol212602-sec-0022}
----------------------------------------------------------------------------

We evaluated overexpression of *GINS1* in BrCa specimens (the same samples used as for validation of *miR‐101‐5p* expression; Fig. [1](#mol212602-fig-0001){ref-type="fig"}A). *GINS1* expression was significantly upregulated in BrCa issues compared with normal tissues (*P* = 0.0020; Fig. [5](#mol212602-fig-0005){ref-type="fig"}A). Spearman\'s rank tests showed a tendency toward an inverse correlation between *GINS1* and *miR‐101‐5p* expression (*P* = 0.0532, *r* = −0.379; Fig. [5](#mol212602-fig-0005){ref-type="fig"}B). We also investigated the inverse correlation between *GINS1* and *miR‐101‐5p* expression in BrCa clinical specimens using TCGA database. An inverse correlation was detected between expression of *miR‐101‐5p* and *GINS1* by Spearman's rank tests (*P* = 0.00103, *r* = −0.082; Fig. S7).

![Expression and significance of *GINS1* in BrCa clinical specimens. (A) Expression levels of *GINS1* in BrCa clinical specimens and two BrCa cell lines (MDA‐MB‐231 and MCF‐7). *GUSB* was used as an internal control. (B) Spearman's rank test showed the negative correlation between *GINS1* expression and *miR‐101‐5p*. (C) Forest plot of multivariate Cox proportional hazards regression analysis of overall survival using data from TCGA database.](MOL2-14-426-g005){#mol212602-fig-0005}

A multivariate Cox proportional hazards model showed that high expression of *GINS1* was an independent predictive factor for survival \[hazard ratio (HR): 1.64, 95% confidence interval (CI): 1.12--2.41, *P* = 0.0102\], as were well‐known clinical prognostic factors such as N stage and M stage (Fig. [5](#mol212602-fig-0005){ref-type="fig"}C). Next, we investigated the expression levels of GINS1 in BrCa clinical specimens by immunostaining. GINS1 was strongly overexpressed in several cancer lesions compared with that in adjacent noncancerous lesions (Fig. [6](#mol212602-fig-0006){ref-type="fig"}). The clinical features of the specimens used to immunostaining are summarized in Table [1](#mol212602-tbl-0001){ref-type="table"}.

![Expression of GINS1 in clinical BrCa tissues. Immunohistochemistry staining of GINS1 in BrCa specimens. Overexpression of GINS1 was observed in cancer cells, whereas negative or low expression of GINS1 was observed in normal cells. Scale bars of ×40 and ×400 represent 1 mm and 100 µm, respectively.](MOL2-14-426-g006){#mol212602-fig-0006}

3.8. Effects of *GINS1* silencing in BrCa cells {#mol212602-sec-0023}
-----------------------------------------------

To validate the oncogenic functions of *GINS1* in BrCa cells, we used knockdown assays with siRNA in two BrCa cell lines, MDA‐MB‐231 and MCF‐7 (Fig. [5](#mol212602-fig-0005){ref-type="fig"}A). The two siRNA, si*GINS1*‐1 and si*GINS*‐2, used in this assay significantly suppressed *GINS1*/GINS1 expression in BrCa cells (Fig. [7](#mol212602-fig-0007){ref-type="fig"}A,B).

![Effects of *GINS1* silencing in BrCa cell lines. (A) MicroRNA expression of *GINS1* 72 h after transfection with si‐*GINS1*‐1 and si‐*GINS1*‐2 in two BrCa cell lines (MDA‐MB‐231 and MCF‐7). *GUSB* was used an internal control (\**P* \< 0.0001). (B) GINS1 protein expression was evaluated by western blot analysis 72 h after transfection with si‐*GINS1*‐1 and si‐*GINS1*‐2 into BrCa cell lines. GAPDH was used as a loading control. (C) Cell proliferation was identified by XTT assays 72 h after transfection with si*GINS1*‐1 and si*GINS1*‐2 (\**P* \< 0.0001). (D) Cell migration activity was determined using migration assays (\**P* \< 0.001, \*\**P* \< 0.0001). (E) Cell invasion was determined by Matrigel invasion assays (\**P* \< 0.01, \*\**P* \< 0.0001). Error bars are represented as mean ± SD. *P*‐values were calculated using Bonferroni‐adjusted Mann‐Whitney *U*‐test.](MOL2-14-426-g007){#mol212602-fig-0007}

Functional assays showed that malignant phenotypes of BrCa cells (e.g. cell proliferation, migration, and invasive abilities) were significantly blocked by si*GINS1* transfection in BrCa cells (Fig. [7](#mol212602-fig-0007){ref-type="fig"}C--E). Furthermore, cell cycle assays showed that G~0~/G~1~ phase arrest was detected in si*GINS1*‐transfected cells (Fig. S3).

Similar results were observed in another cell line, MDA‐MB‐157. Indeed, ectopic expression of *miR‐101‐5p* and knockdown of *GINS1* significantly blocked cancer cell aggressive phenotypes in MDA‐MB‐157 cells (Fig. S8).

3.9. Genes affected by GINS1 expression in BrCa clinical specimens {#mol212602-sec-0024}
------------------------------------------------------------------

Finally, we identified the differentially expressed genes that were affected by *GINS1* in BrCa. Our strategy is shown in Fig. S9. GSEA for the differentially expressed genes in BrCa tissues showing high expression of *GINS1* in TCGA identified 11 signaling pathways (Fig. S10). We categorized *GINS1*‐regulated genes using KEGG pathways. In total, seven pathways were identified based on overexpressed genes in BrCa tissues showing high *GINS1* expression in TCGA (Fig. [8](#mol212602-fig-0008){ref-type="fig"}A). In particular, genes involved in DNA replication pathways were identified by heatmap analysis (Fig. [8](#mol212602-fig-0008){ref-type="fig"}B).

![Genes affected by *GINS1* expression in BrCa clinical specimens. (A) Identification of overexpressed genes affected by *GINS1* expression in BrCa tissues in TCGA‐BrCa and categorized by KEGG pathways. (B) Heatmap analysis of genes involved in DNA replication pathways. (C) The clinical significance of *MCM4, MCM6*, and *RFC3* expression in BrCa. Kaplan--Meier overall survival curve analyses of patients with BrCa using data from TCGA database. Patients were divided into two groups according to miRNA expression and analyzed.](MOL2-14-426-g008){#mol212602-fig-0008}

Among these genes involved in DNA replication pathways, we investigated the clinical significance of the relationship between gene expression and prognosis of the patients with BrCa by TCGA database analysis. High expression of four genes (*GINS1*, *MCM4*, *MCM6*, and *RFC3*) was significantly associated with poor prognosis in patients with BrCa (Fig. [8](#mol212602-fig-0008){ref-type="fig"}C).

4. Discussion {#mol212602-sec-0025}
=============

Notably, a single miRNA regulates a wide range of different RNA transcripts (protein‐coding and non‐protein‐coding genes) in various normal and abnormal cells. Based on the unique nature of miRNA, novel RNA networks in human cancer cells can be identified from analysis of relevant miRNA. Currently available high‐throughput technologies, e.g. oligo‐microarrays, PCR‐based arrays, and RNA‐sequencing, have enabled the construction of miRNA expression signatures of BrCa (Ma *et al.*, [2018](#mol212602-bib-0030){ref-type="ref"}), revealing the abnormal expression of many miRNA (Adhami *et al.*, [2018](#mol212602-bib-0001){ref-type="ref"}; Gupta *et al.*, [2019](#mol212602-bib-0015){ref-type="ref"}; Khordadmehr *et al.*, [2019](#mol212602-bib-0021){ref-type="ref"}; Klinge, [2018](#mol212602-bib-0022){ref-type="ref"}; Kurozumi *et al.*, [2017](#mol212602-bib-0025){ref-type="ref"}; Mehrgou and Akouchekian, [2017](#mol212602-bib-0035){ref-type="ref"}). One approach to identify the most important miRNA from a large number of candidate miRNA is to identify crossovers of miRNA that have been reported in multiple independent studies. Previous studies have shown that *miR‐139‐5p*, *miR‐195‐3p*, *miR‐205‐3p*, and *miR‐99a‐5p* are frequently downregulated and function as tumor‐suppressive miRNA in BrCa cells(Adhami *et al.*, [2018](#mol212602-bib-0001){ref-type="ref"}; Gupta *et al.*, [2019](#mol212602-bib-0015){ref-type="ref"}; Khordadmehr *et al.*, [2019](#mol212602-bib-0021){ref-type="ref"}; Klinge, [2018](#mol212602-bib-0022){ref-type="ref"}; Kurozumi *et al.*, [2017](#mol212602-bib-0025){ref-type="ref"}; Mehrgou and Akouchekian, [2017](#mol212602-bib-0035){ref-type="ref"}). These miRNA were included in the signature we created in this study.

Furthermore, a major advantage of this signature is that it contained multiple passenger strands of miRNA derived from miRNA duplexes, e.g. *miR‐99a‐3p*, *miR‐101‐5p*, *miR‐144‐5p*, and *miR‐145‐3p*. As a general theory of miRNA biogenesis, the guide strand of miRNA derived from the miRNA duplex is incorporated into the RISC and regulates gene expression (Bhayani *et al.*, [2012](#mol212602-bib-0005){ref-type="ref"}; Mah *et al.*, [2010](#mol212602-bib-0032){ref-type="ref"}; McCall *et al.*, [2017](#mol212602-bib-0034){ref-type="ref"}). In contrast, the passenger strand is degraded and does not regulate genes in cells (Bhayani *et al.*, [2012](#mol212602-bib-0005){ref-type="ref"}; Mah *et al.*, [2010](#mol212602-bib-0032){ref-type="ref"}; McCall *et al.*, [2017](#mol212602-bib-0034){ref-type="ref"}). However, our recent studies have shown that some passenger miRNA have tumor‐suppressive functions in cancer cells (e.g. *miR‐144‐5p*, *miR‐145‐3p*, *miR‐150‐3p*, and *miR‐455‐5p*) (Arai *et al.*, [2019](#mol212602-bib-0002){ref-type="ref"}; Misono *et al.*, [2018](#mol212602-bib-0036){ref-type="ref"}; Misono *et al.*, [2019](#mol212602-bib-0037){ref-type="ref"}; Uchida *et al.*, [2019](#mol212602-bib-0052){ref-type="ref"}). These miRNA and their target oncogenic genes are closely associated with cancer pathogenesis (Arai *et al.*, [2019](#mol212602-bib-0002){ref-type="ref"}; Misono *et al.*, [2018](#mol212602-bib-0036){ref-type="ref"}; Misono *et al.*, [2019](#mol212602-bib-0037){ref-type="ref"}; Uchida *et al.*, [2019](#mol212602-bib-0052){ref-type="ref"}). In the future, we will attempt to clarify the new molecular networks of BrCa using passenger strands of miRNA as indicators.

We focused on *miR‐101‐5p* and explored new aspects of this miRNA in BrCa cells. Many studies have shown that downregulation of *miR‐101‐3p* (the guide strand) occurs frequently in many cancers and that this miRNA acts as a tumor suppressor (Wang *et al.*, [2018](#mol212602-bib-0054){ref-type="ref"}). Previous studies have clarified that *miR‐101‐3p* regulates various pivotal oncogenes and that downregulation of this miRNA affects cancer cell proliferation, metastasis, drug resistance, and angiogenesis via targeting of several oncogenic targets, e.g. *EZH2*, *STMN1*, *VHL*, *SOX2*, and *DNMT3A* (Wang *et al.*, [2018](#mol212602-bib-0054){ref-type="ref"}). In BrCa, downregulation of *miR‐101‐3p* was detected in all subtypes of BrCa tissues, and *miR‐101‐3p* acted as a tumor suppressor (Liu *et al.*, [2015](#mol212602-bib-0029){ref-type="ref"}; Liu *et al.*, [2016](#mol212602-bib-0028){ref-type="ref"}; Ren *et al.*, [2012](#mol212602-bib-0042){ref-type="ref"}; Zhang *et al.*, [2019](#mol212602-bib-0059){ref-type="ref"}, [2015](#mol212602-bib-0060){ref-type="ref"}, [2019](#mol212602-bib-0059){ref-type="ref"}, [2015](#mol212602-bib-0060){ref-type="ref"}). Compared with reports of *miR‐101‐3p*, few studies have reported the tumor‐suppressive functions of *miR‐101‐5p* and its target molecules in cancer cells. More recently, downregulation of *miR‐101‐5p* was reported in non‐small cell lung carcinoma tissues compared with that in normal tissues (Chen *et al.*, [2019](#mol212602-bib-0008){ref-type="ref"}). Overexpression of *miR‐101‐5p* was shown to suppress the aggressive phenotypes of cancer cells (*in vitro*) and pulmonary metastasis (*in vivo*) by regulating *CXCL6* (Chen *et al.*, [2019](#mol212602-bib-0008){ref-type="ref"}). Our data also showed that *miR‐101‐5p* acted as an antitumor miRNA in BrCa cells. Notably, both strands of miRNA derived from the *miR‐101* duplex were found to have tumor‐suppressive functions in cancer cells.

Next, we aimed to elucidate *miR‐101‐5p*‐regulated oncogenes and oncogenic pathways in BrCa cells. Analysis of our miRNA target search revealed that seven genes (*HMGB3*, *ESRP1*, *GINS1*, *TPD52*, *SRPK1*, *VANGL1*, and *MAGOHB*) were closely associated with poor prognosis. Among these targets, three genes (*GINS1*, *TPD52*, and *SRPK1*) were strongly controlled by *miR‐101‐5p* in BrCa cells. Aberrant expression of *TPD52* (encoding *TPD52*) has been reported in a wide range of cancers, including BrCa, and several tumor‐suppressive miRNA have been reported to be involved in regulating the expression of these genes (Balleine *et al.*, [2000](#mol212602-bib-0003){ref-type="ref"}; Byrne *et al.*, [2014](#mol212602-bib-0007){ref-type="ref"}; Li *et al.*, [2016](#mol212602-bib-0027){ref-type="ref"}; Roslan *et al.*, [2014](#mol212602-bib-0043){ref-type="ref"}). *SRPK1* (encoding serine‐arginine protein kinase 1) is involved in the regulation of several mRNA processing pathways, and its overexpression has been reported in multiple cancers (Patel *et al.*, [2019](#mol212602-bib-0040){ref-type="ref"}). High expression of *SRPK1* is correlated with poor disease outcomes in patients with BrCa (Hayes *et al.*, [2007](#mol212602-bib-0016){ref-type="ref"}; van Roosmalen *et al.*, [2015](#mol212602-bib-0053){ref-type="ref"}). Knockdown of *SRPK* in BrCa cells inhibits metastasis to distant organs (Hayes *et al.*, [2007](#mol212602-bib-0016){ref-type="ref"}; van Roosmalen *et al.*, [2015](#mol212602-bib-0053){ref-type="ref"}). Further functional analyses of these genes will reveal the biological characteristics of BrCa. Starting from antitumor miRNA and using TCGA database analyses, we were able to identify effective prognostic markers and therapeutic targets for BrCa, indicating that our miRNA‐based strategy was feasible.

In this study, we focused on *GINS1* and showed that its aberrant expression was closely related to BrCa malignant phenotypes. Chromosomal DNA replication is a tightly controlled essential process in the eukaryotic cell cycle, and many proteins are involved in each step of DNA replication (Labib and Gambus, [2007](#mol212602-bib-0026){ref-type="ref"}; MacNeill, [2010](#mol212602-bib-0031){ref-type="ref"}; Seo and Kang, [2018](#mol212602-bib-0044){ref-type="ref"}; Sun *et al.*, [2016](#mol212602-bib-0048){ref-type="ref"}). The GINS complex (*SLD5*, *GINS1*, *GINS2*, and *GINS3*) is involved in the minichromosome maintenance complex and Cdc45 with proteins in a replisome progression complex (Labib and Gambus, [2007](#mol212602-bib-0026){ref-type="ref"}; MacNeill, [2010](#mol212602-bib-0031){ref-type="ref"}; Seo and Kang, [2018](#mol212602-bib-0044){ref-type="ref"}; Sun *et al.*, [2016](#mol212602-bib-0048){ref-type="ref"}). A previous study of *GINS1* in BrCa cells showed that knockdown of *GINS1* inhibited BrCa cell growth by delaying DNA replication (Nakahara *et al.*, [2010](#mol212602-bib-0039){ref-type="ref"}). This result was consistent with our current data. Another study showed that high expression of *GINS1* in cancer cells promoted cell proliferation, transplantation, and metastatic properties (Nagahama *et al.*, [2010](#mol212602-bib-0038){ref-type="ref"}). Overexpression of *PSF1* was reported non‐small lung cancers, and its expression was useful as a prognostic marker (Kanzaki *et al.*, [2016](#mol212602-bib-0020){ref-type="ref"}). These findings indicated that aberrantly expressed *GINS1* was involved in cancer pathogenesis.

Anlotinib is a newly developed multitarget receptor tyrosine kinase inhibitor used for patients with treatment failure non‐small cell lung cancer with metastases (Shen *et al.*, [2018](#mol212602-bib-0045){ref-type="ref"}). Interestingly, *GINS1* was identified as an anlotinib‐mediated downstream gene, and knockdown of *GINS1* markedly inhibited the proliferation of synovial sarcoma cells (Tang *et al.*, [2019](#mol212602-bib-0049){ref-type="ref"}). Aberrant expression of cell cycle‐regulated genes is a common molecular mechanism of cancer cell malignancies, and these genes are potential cancer therapeutic targets. Cyclin‐dependent kinases, i.e. CDK4 and CDK6, are essential for transition from the G~0~/G phase to the S phase of the cell cycle. Recently, several CDK4/6 inhibitors (e.g. abemaciclib, palbociclib, and ribociclib) have been developed, and several clinical trials have demonstrated the therapeutic effects of these inhibitors on hormone receptor‐positive/HER‐negative BrCa (Iwata, [2018](#mol212602-bib-0019){ref-type="ref"}; Matutino *et al.*, [2018](#mol212602-bib-0033){ref-type="ref"}; Spring *et al.*, [2019](#mol212602-bib-0047){ref-type="ref"}). Clinical trials of CDK4/6 inhibitors are also progressing in other subtypes of BrCa (Iwata, [2018](#mol212602-bib-0019){ref-type="ref"}; Spring *et al.*, [2019](#mol212602-bib-0047){ref-type="ref"}). Our current data showed that knockdown of *GINS1* could markedly suppress malignant phenotypes in BrCa cells by affecting several cell cycle‐ and DNA replication‐controlled genes. Controlling genes involved in DNA replication may represent a potential approach for cancer treatment. Thus, *GINS1* could be a novel diagnostic and therapeutic target for patients with BrCa.

5. Conclusion {#mol212602-sec-0026}
=============

We produced a novel RNA‐sequencing‐based BrCa miRNA signature. Our signature revealed that several novel miRNA, including passenger strands of miRNA, were downregulated in BrCa tissues. The BrCa miRNA signature created in this study established a basis for exploring new molecular RNA networks in BrCa. This is the first report demonstrating that *miR‐101‐5p* (the passenger strand of the *miR‐101* duplex) acted as a tumor‐suppressive miRNA in BrCa cells. Several oncogenic targets regulated by *miR‐101‐5p* were closely associated with BrCa pathogenesis and oncogenesis. Moreover, we demonstrated that *GINS1*, which we identified from analyses of genes regulated by *miR‐101‐5p*, may be a novel diagnostic and therapeutic target in BrCa. Our approach based on analysis of miRNA signatures could contribute to elucidation of the molecular pathogenesis of cancer.
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**Fig. S1** **.** A partial sequence of the 3′ untranslated region (3′‐UTR) of the GINS1 gene. A putative binding site for *miR‐101‐5p* is shown in the 3′‐UTR.

###### 

Click here for additional data file.

###### 

**Fig. S2** **.** Sequences of *miR‐101‐1* and *miR‐101‐2* in the human genome. Stem‐loop sequences of *miR‐101‐1* and *miR‐101‐2*; red characters indicate mature miRNA.

###### 

Click here for additional data file.

###### 

**Fig. S3** **.** Cell cycle assays (flow cytometry) in MDA‐MB‐231 cells with ectopic expression of *miR‐101‐5p* and si*GINS1*. Cell cycle phase distributions (G~0~/G~1~, S, and G2/M) are shown in the bar chart. By transfection of *miR‐101‐5p* and si*GINS1*, G~0~/G~1~ phase arrest was detected in MDA‐MB‐231 cells.
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**Fig. S4** **.** Incorporation of *miR‐101‐5p* into the RISC in BrCa cells. Mature miRNA (*miR‐101‐5p* and *miR‐101‐3p*) were transfected into MAD‐MB‐231 cells, and incorporated miRNA was immunoprecipitated using anti‐Ago2 antibodies. Incorporated miRNA was evaluated by qRT‐PCR (\**P* \< 0.0001). Expression of *miR‐21‐5p* was used for normalization. Error bars are represented as mean ± SD. *P*‐values were calculated using Bonferroni‐adjusted Mann‐Whitney U‐test.
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**Fig. S5** **.** The strategy for identification of *miR‐101‐5p* target oncogenes in BrCa cells.
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**Fig. S6** **.** Direct regulation of TPD52 and SRPK1 by *miR‐101‐5p* in BrCa cells. Dual luciferase reporter assays showed that luminescence activities were reduced by cotransfection with wild‐type vectors (A: TPD52 and B: SRPK1) and *miR‐101‐5p* in MDA‐MB‐231 cells. Normalized data were calculated as Renilla/firefly luciferase activity ratios (\**P* \< 0.001). Error bars are represented as mean ± SD. *P*‐values were calculated using Bonferroni‐adjusted Mann‐Whitney U‐test.
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**Fig. S7** **.** Inverse correlation between expression of *miR‐101‐5p* and *GINS1*in BrCa patients (TCGA database analysis, *n* = 1006), as detected by Spearman's rank tests (*P* = 0.00103, *r* = --0.082).
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**Fig. S8** **.** Expression of GINS1 was significantly reduced by si*GINS1* transfection into MDA‐MB‐157 cells (A). Functional assays, cell proliferation (B), migration (C), and invasion (D), in MDA‐MB‐157 cells with transfection of *miR‐101‐5p* and si*GINS1*. Cell proliferation, migration, and invasion assays were described in Materials and Methods (2.4 and 2.5). \**P* \< 0.001, \*\**P* \< 0.05. Error bars are represented as mean ± SD. *P*‐values were calculated using Bonferroni‐adjusted Mann‐Whitney U‐test.
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**Fig. S9** **.** The strategy for identification of GINS1 affected genes/pathways in BrCa tissues in TCGA.
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**Fig. S10** **.** Gene set enrichment analysis (GSEA) based on mRNA sequence data in TCGA‐BrCa tissues.
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**Table S1** **.** Reagents used in this study.
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**Table S2** **.** Annotation of reads aligned to small RNA.
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**Table S3** **.** Downregulated miRNA in BrCa compare with normal breast (guide/passenger strand).
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